Raymond James analyst Steven Seedhouse resumed coverage of Alexion with an Outperform rating and $161 price target, citing what he sees as good visibility into continued growth as the company works to switch patients from Soliris to Ultomiris and pursues subcutaneous follow-on products to extend “existing, successful franchises.” He models upside even without any pipeline contributions, the analyst noted.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.